Cocaine esterase

Drug Profile

Cocaine esterase

Alternative Names: RBP-8000; T172R/G173G cocaine esterase

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Antidotes; Carboxylic ester hydrolases
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse

Most Recent Events

  • 22 Feb 2016 Phase-II development is ongoing in USA
  • 23 Dec 2014 Reckitt Benckiser Pharmaceuticals is now called Indivior
  • 30 Nov 2013 Reckitt Benckiser completes a phase II trial in Cocaine abuse in USA (NCT01846481)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top